Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the compan...

The UK and some EU countries allow this drug for pregnant women and during the periconceptional phase. So far, doctors in India prescribe i...

Alkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...

India's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...

Tenglyn, is a product belonging to a new class of drugs called gliptins, a segment that has witnessed the most aggressive growth among all ...

The drug has been jointly developed by two CSIR laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medici...

Earlier, in an interim order, a division bench of the high Court had restrained Glenmark from making or selling its drug, used for treatmen...

With Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.

The Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.

Delhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.

The court's order came on MSD's plea alleging that the Indian pharma company has violated its intellectual property right (IPR) over its an...

Healthcare major, Zydus Cadila has filed IND (Investigational New Drug) application for anti-diabetic and anti-obesity drug with Drugs Cont...